CA2084204A1 - Derive arylalcanoylamine et medicament en renfermant - Google Patents

Derive arylalcanoylamine et medicament en renfermant

Info

Publication number
CA2084204A1
CA2084204A1 CA002084204A CA2084204A CA2084204A1 CA 2084204 A1 CA2084204 A1 CA 2084204A1 CA 002084204 A CA002084204 A CA 002084204A CA 2084204 A CA2084204 A CA 2084204A CA 2084204 A1 CA2084204 A1 CA 2084204A1
Authority
CA
Canada
Prior art keywords
thioprolyl
prolyl
group
tetrahydronaphthalen
ylacetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002084204A
Other languages
English (en)
Inventor
Akihiro Okubo
Hiroyasu Nishioka
Heihachiro Arai
Yoshiaki Tanaka
Hisayoshi Kato
Naoki Nakata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zeria Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2084204A1 publication Critical patent/CA2084204A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002084204A 1990-06-07 1991-06-07 Derive arylalcanoylamine et medicament en renfermant Abandoned CA2084204A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP147281/1990 1990-06-07
JP14728190 1990-06-07

Publications (1)

Publication Number Publication Date
CA2084204A1 true CA2084204A1 (fr) 1991-12-08

Family

ID=15426662

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002084204A Abandoned CA2084204A1 (fr) 1990-06-07 1991-06-07 Derive arylalcanoylamine et medicament en renfermant

Country Status (8)

Country Link
US (1) US5407950A (fr)
EP (1) EP0536399B1 (fr)
AT (1) ATE133407T1 (fr)
AU (1) AU643300B2 (fr)
CA (1) CA2084204A1 (fr)
DE (1) DE69116692T2 (fr)
DK (1) DK0536399T3 (fr)
WO (1) WO1991018877A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536737A (en) 1992-11-20 1996-07-16 Japan Tobacco Inc. Compound having prolyl endopeptidase inhibitory activity and pharmaceutical use thereof
JP3810097B2 (ja) * 1993-01-15 2006-08-16 明治製菓株式会社 ピロリジン−２−イルカルボニル複素環式化合物誘導体
CN1362947A (zh) 1999-03-15 2002-08-07 Axys药物公司 用作蛋白酶抑制剂的n－氰基甲基酰胺
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
JP2004523506A (ja) 2000-12-22 2004-08-05 アクシス・ファーマシューティカルズ・インコーポレイテッド カテプシン阻害剤としての新規な化合物と組成物
EP1436255A1 (fr) 2001-09-14 2004-07-14 Aventis Pharmaceuticals, Inc. Nouveaux composes et nouvelles compositions utiles comme inhibiteurs de la cathepsine
YU34604A (sh) 2001-11-14 2006-08-17 Aventis Pharmaceuticals Inc. Oligopeptidi kao inhibitori katepsina s i kompozicije koje ih sadrže
FI20030014A0 (fi) * 2003-01-03 2003-01-03 Orion Corp Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä
JP4806628B2 (ja) 2003-05-05 2011-11-02 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤
EP2338490A3 (fr) 2003-11-03 2012-06-06 Probiodrug AG Combinaisons utiles pour le traitement de désordres neuronales
US7304086B2 (en) 2004-02-05 2007-12-04 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2006239929B2 (en) * 2005-04-22 2011-11-03 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-IV inhibitors
EP1760076A1 (fr) 2005-09-02 2007-03-07 Ferring B.V. Inhibiteur de FAP
EP2089383B1 (fr) 2006-11-09 2015-09-16 Probiodrug AG Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
US8524654B2 (en) * 2007-05-21 2013-09-03 The Uab Research Foundation Prolyl endopeptidase inhibitors for reducing or preventing neutrophilic inflammation
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
WO2011107530A2 (fr) 2010-03-03 2011-09-09 Probiodrug Ag Nouveaux inhibiteurs
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
WO2011131748A2 (fr) 2010-04-21 2011-10-27 Probiodrug Ag Nouveaux inhibiteurs
EP2686313B1 (fr) 2011-03-16 2016-02-03 Probiodrug AG Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase
DE102016116130A1 (de) * 2016-08-30 2018-03-01 Universität Bielefeld Verfahren zur Herstellung chiraler Aminonitrile
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1309805C (fr) * 1985-04-16 1992-11-03 Naoki Higuchi Derive dipeptidique, sa synthese et son utilisation
JP2526084B2 (ja) * 1987-02-23 1996-08-21 小野薬品工業株式会社 新規なチアゾリジン誘導体
DE3712364A1 (de) * 1987-04-11 1988-10-27 Hoechst Ag Neue pyrrolidin-2-(1,3-dicarbonyl)-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel sowie deren verwendung
US4857524A (en) * 1987-08-08 1989-08-15 Kissei Pharmaceutical Co., Ltd. Thiazolidine compounds and therapeutic method
JPH0670023B2 (ja) * 1987-08-08 1994-09-07 キッセイ薬品工業株式会社 チアゾリジン誘導体
JPH01250370A (ja) * 1987-12-23 1989-10-05 Zeria Pharmaceut Co Ltd 新規アミノ酸イミド誘導体、製法ならびに用途
US5212191A (en) * 1988-04-08 1993-05-18 Ono Pharmaceutical Co., Ltd. Heterocyclic compounds
US5053414A (en) * 1988-04-08 1991-10-01 Ono Pharmaceutical Co., Ltd. Heterocyclic compounds
CA2004028C (fr) * 1988-12-08 1998-09-22 Motoki Torizuka Derives condenses de benzene
WO1990012005A1 (fr) * 1989-04-13 1990-10-18 Japan Tobacco Inc. Nouveaux derives aminoacides possedant une activite d'inhibiteur de la prolylendopeptidase

Also Published As

Publication number Publication date
AU643300B2 (en) 1993-11-11
US5407950A (en) 1995-04-18
DE69116692D1 (de) 1996-03-07
EP0536399A4 (en) 1993-04-21
DE69116692T2 (de) 1996-09-05
WO1991018877A1 (fr) 1991-12-12
AU7986691A (en) 1991-12-31
ATE133407T1 (de) 1996-02-15
EP0536399B1 (fr) 1996-01-24
DK0536399T3 (da) 1996-06-03
EP0536399A1 (fr) 1993-04-14

Similar Documents

Publication Publication Date Title
CA2084204A1 (fr) Derive arylalcanoylamine et medicament en renfermant
EP1680418B1 (fr) Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
US5965562A (en) Aroyl-piperidine derivatives
DE69808017T2 (de) D-Prolinderivate
DE60219295T2 (de) Acylierte piperidinderivate als melanocortin-4-rezeptoragonisten
US7544708B2 (en) Azabicyclo derivatives as muscarinic receptor antagonists
US9469609B2 (en) Synthesis of pyrrolidine compounds
JP2002531547A (ja) Ｎ置換されている２−シアノピロリジン
US5814636A (en) Compounds with platelet aggregation inhibitor activity
CA2255625A1 (fr) Nouveaux derives d'acides amines et leur utilisation en tant qu'inhibiteurs de la trombine
NZ232542A (en) N-phenyl-n-(4-piperidinyl)amide derivatives; preparatory processes and pharmaceutical compositions
US20110130432A1 (en) Heterocyclic Carboxamides For Use As Thrombin Inhibitors
JPH049367A (ja) アリールアルカノイル誘導体，該化合物の製造中間体及びそれらを含有する医薬
CA1334416C (fr) Derives 4-phenyl-4¬n-(phenyl)amido|piperidine et compositions pharmaceutiques et methodes utilisant ces produits
US4719207A (en) CNS active substituted azetidinone compounds
DE69217613T2 (de) Stickstoff enthaltende bizyklische Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
IL197962A (en) Crystalline form of –3– (1 h– indole – 3 – yl) –4– [2– (4 – methyl – piperazine – 1 – yl) –quinazoline – 4 – yl] –pyrol – 2,5 – deion acetate, preparation A medical containing it, a process for its preparation and its use in the preparation of pharmacological material
WO2008148279A1 (fr) Dérivés de pyrrolidine condensés avec du cyclobutyle, leurs procédés de préparation et leur utilisation médicale
JPH08501567A (ja) レニン阻害ｎ−（２−アミノ−２−オキソエチル）ブタンジアミド誘導体
IE54501B1 (en) Ergot alkaloids
JP3190717B2 (ja) 新規な置換イタコン酸誘導体
JPWO1991018877A1 (ja) 新規アリールアルカノイルアミン誘導体及びこれを含有する医薬
HK1082728B (en) Azabicyclo derivatives as muscarinic receptor antagonists
HK1172030B (en) Synthesis of pyrrolidine compounds
HK1172030A1 (en) Synthesis of pyrrolidine compounds

Legal Events

Date Code Title Description
FZDE Discontinued